Trials / Completed
CompletedNCT02193217
A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 81 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to explore the cardiac pharmacodynamics, safety and tolerability of MT-1303 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-1303-Low | |
| DRUG | MT-1303-High | |
| DRUG | Fingolimod | |
| DRUG | Placebo |
Timeline
- Primary completion
- 2014-12-01
- Completion
- 2015-01-01
- First posted
- 2014-07-17
- Last updated
- 2015-02-20
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02193217. Inclusion in this directory is not an endorsement.